AMGEN INC (AMGN) Stock Price, Quote, News and Overview
NASDAQ:AMGN - Nasdaq - US0311621009 - Common Stock - Currency: USD
AMGN Quote, Performance and Key Statistics
AMGEN INC
NASDAQ:AMGN (1/23/2025, 6:32:44 PM)
After market: 277.88 0 (0%)277.88
+4.44 (+1.62%)
The current stock price of AMGN is 277.88 USD. In the past month the price increased by 5.51%. In the past year, price decreased by -10.87%.
AMGN Latest News, Press Releases and Analysis
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
deCODE genetics: Mapa completo de recombinación del genoma humano, un gran paso en la genética
/PRNewswire/ -- Los cientÃficos de deCODE genetics/Amgen han elaborado un mapa completo de cómo se mezcla el ADN humano a medida que se transmite durante la...
deCODE genetics: Complete recombination map of the human-genome, a major step in genetics
/PRNewswire/ -- Scientists at deCODE genetics/Amgen have constructed a complete map of how human DNA is mixed as it is passed down during reproduction. The map...
deCODE genetics: Vollständige Rekombinationskarte des menschlichen Genoms, ein wichtiger Schritt in der Genetik
/PRNewswire/ -- Wissenschaftler von deCODE genetics/Amgen haben eine vollständige Karte erstellt, die zeigt, wie die menschliche DNA bei der Weitergabe während...
deCODE genetics : carte de recombinaison complète du génome humain, une étape majeure en génétique
/PRNewswire/ -- Les scientifiques de deCODE genetics/Amgen ont construit une carte complète de la façon dont l'ADN humain est mélangé lorsqu'il est transmis...
FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in combination with...
AMGN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.88 | 301.60B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.80B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862.22 | 113.24B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.29 | 76.33B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.43B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.66B | ||
| NTRA | NATERA INC | N/A | 22.68B | ||
| BIIB | BIOGEN INC | 8.8 | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.18B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.33 | 16.60B |
Related screens
About AMGN
Company Profile
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 26,700 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. The company operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Company Info
AMGEN INC
One Amgen Center Drive
Thousand Oaks CALIFORNIA 91320 US
CEO: Robert A. Bradway
Employees: 26700
Company Website: https://www.amgen.com/
Investor Relations: https://investors.amgen.com
Phone: 18054471000
AMGN FAQ
What is the price of AMGN?
The current price of AMGN is 277.88 USD.
What is the symbol for AMGEN INC?
The exchange symbol of AMGEN INC is AMGN and it is listed on the Nasdaq exchange.
On which exchange is AMGN listed?
AMGN is listed on the Nasdaq exchange.
Is AMGN a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for AMGN, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of AMGN.
Does AMGN pay dividends?
AMGN has a dividend yield of 3.53%. The yearly dividend amount is currently 8.52.
When does AMGN report earnings?
AMGN will report earnings on 2025-02-04, after the market close.
What is the Price/Earnings (PE) ratio of AMGN?
The PE ratio for AMGN is 14.46. This is based on the reported non-GAAP earnings per share of 19.22 and the current share price of 277.88 USD.
What is the Short Interest ratio of AMGN?
The outstanding short interest for AMGN is 2.08% of its float.
AMGN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AMGN. When comparing the yearly performance of all stocks, AMGN is a bad performer in the overall market: 81.49% of all stocks are doing better.
AMGN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to AMGN. AMGN scores excellent on profitability, but there are concerns on its financial health.
AMGN Financial Highlights
Over the last trailing twelve months AMGN reported a non-GAAP Earnings per Share(EPS) of 19.22. The EPS increased by 6.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13% | ||
| ROA | 4.65% | ||
| ROE | 56.2% | ||
| Debt/Equity | 7.55 |
AMGN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 73% to AMGN. The Buy consensus is the average rating of analysts ratings from 39 analysts.
For the next year, analysts expect an EPS growth of 3.59% and a revenue growth 17.88% for AMGN